Combination pharmaceutical therapies for obesity (Q57314317)

https://api.crossref.org/works/10.1517%2F14656560902824152

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

National trends in antiobesity medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Multiple neural systems controlling food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Central nervous system regulation of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Bupropion for weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902824152

Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4780673

What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4780673

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4780673

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4780673

The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial

2 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19351275

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term persistence with orlistat and sibutramine in a population-based cohort

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19351275